Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 434

1.

Clinical consequences of developmental programming of low nephron number.

Luyckx VA, Brenner BM.

Anat Rec (Hoboken). 2019 Oct 6. doi: 10.1002/ar.24270. [Epub ahead of print]

PMID:
31587509
2.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.

Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V.

Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11.

3.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

PMID:
30990260
4.

N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.

Idzerda NMA, Persson F, Pena MJ, Brenner BM, Brunel P, Chaturvedi N, McMurray JJ, Parving HH, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Dec;20(12):2899-2904. doi: 10.1111/dom.13465. Epub 2018 Aug 5.

5.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

6.

Proximal Aberrant Crypt Foci Associate with Synchronous Neoplasia and Are Primed for Neoplastic Progression.

Drew DA, Mo A, Grady JJ, Stevens RG, Levine JB, Brenner BM, Anderson JC, Forouhar F, O'Brien MJ, Devers TJ, Rosenberg DW.

Mol Cancer Res. 2018 Mar;16(3):486-495. doi: 10.1158/1541-7786.MCR-17-0380. Epub 2017 Dec 8.

7.

A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group.

Luyckx VA, Perico N, Somaschini M, Manfellotto D, Valensise H, Cetin I, Simeoni U, Allegaert K, Vikse BE, Steegers EA, Adu D, Montini G, Remuzzi G, Brenner BM; writing group of the Low Birth Weight and Nephron Number Working Group.

Lancet. 2017 Jul 22;390(10092):424-428. doi: 10.1016/S0140-6736(17)30576-7. Epub 2017 Mar 9. No abstract available.

8.

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.

Lancet Diabetes Endocrinol. 2016 Apr;4(4):309-17. doi: 10.1016/S2213-8587(15)00469-6. Epub 2016 Jan 14.

PMID:
26774608
9.

Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.

Heerspink HJ, Ninomiya T, Persson F, Brenner BM, Brunel P, Chaturvedi N, Desai AS, Haffner SM, Mcmurray JJ, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2016 Feb;18(2):169-77. doi: 10.1111/dom.12600. Epub 2016 Jan 13.

PMID:
26511599
10.

Birth weight, malnutrition and kidney-associated outcomes--a global concern.

Luyckx VA, Brenner BM.

Nat Rev Nephrol. 2015 Mar;11(3):135-49. doi: 10.1038/nrneph.2014.251. Epub 2015 Jan 20. Review.

PMID:
25599618
11.

Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease.

Luyckx VA, Bertram JF, Brenner BM, Fall C, Hoy WE, Ozanne SE, Vikse BE.

Lancet. 2013 Jul 20;382(9888):273-83. doi: 10.1016/S0140-6736(13)60311-6. Epub 2013 May 31. Review.

PMID:
23727166
12.

Aliskiren in type 2 diabetes and cardiorenal end points.

Pfeffer MA, Brenner BM, McMurray JJ.

N Engl J Med. 2013 Mar 14;368(11):1065-6. doi: 10.1056/NEJMc1300257. No abstract available.

PMID:
23484839
13.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

14.

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Nicolaides M, Richard A, Xiang Z, Armbrecht J, Pfeffer MA; ALTITUDE Investigators.

J Renin Angiotensin Aldosterone Syst. 2012 Sep;13(3):387-93. doi: 10.1177/1470320311434818. Epub 2012 Feb 14.

PMID:
22333485
15.

Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy.

Anderson JC, Swede H, Rustagi T, Protiva P, Pleau D, Brenner BM, Rajan TV, Heinen CD, Levine JB, Rosenberg DW.

Cancer Causes Control. 2012 Feb;23(2):355-61. doi: 10.1007/s10552-011-9884-7. Epub 2011 Dec 21.

PMID:
22187142
16.

Vitamin D resistance and colon cancer prevention.

Giardina C, Madigan JP, Tierney CA, Brenner BM, Rosenberg DW.

Carcinogenesis. 2012 Mar;33(3):475-82. doi: 10.1093/carcin/bgr301. Epub 2011 Dec 16. Review.

17.

Low nephron number and its clinical consequences.

Luyckx VA, Shukha K, Brenner BM.

Rambam Maimonides Med J. 2011 Oct 31;2(4):e0061. doi: 10.5041/RMMJ.10061. Print 2011 Oct.

18.

Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.

Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ.

Hypertension. 2011 Jul;58(1):2-7. doi: 10.1161/HYPERTENSIONAHA.111.171488. Epub 2011 May 31.

PMID:
21632472
19.

Genomic instability measured by inter-(simple sequence repeat) PCR and high-resolution microsatellite instability are prognostic of colorectal carcinoma survival after surgical resection.

Brenner BM, Swede H, Jones BA, Anderson GR, Stoler DL.

Ann Surg Oncol. 2012 Jan;19(1):344-50. doi: 10.1245/s10434-011-1708-1. Epub 2011 Apr 13.

20.

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ.

Kidney Int. 2011 Aug;80(3):282-7. doi: 10.1038/ki.2011.79. Epub 2011 Mar 30.

21.

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Miao Y, Dobre D, Heerspink HJ, Brenner BM, Cooper ME, Parving HH, Shahinfar S, Grobbee D, de Zeeuw D.

Diabetologia. 2011 Jan;54(1):44-50. doi: 10.1007/s00125-010-1922-6. Epub 2010 Sep 30. Erratum in: Diabetologia. 2011 Aug;54(8):2209.

22.

Comparison of different measures of urinary protein excretion for prediction of renal events.

Lambers Heerspink HJ, Gansevoort RT, Brenner BM, Cooper ME, Parving HH, Shahinfar S, de Zeeuw D.

J Am Soc Nephrol. 2010 Aug;21(8):1355-60. doi: 10.1681/ASN.2010010063. Epub 2010 Jul 15.

23.

High-throughput SNP/CGH approaches for the analysis of genomic instability in colorectal cancer.

Brenner BM, Rosenberg D.

Mutat Res. 2010 Nov 10;693(1-2):46-52. doi: 10.1016/j.mrfmmm.2010.04.002. Epub 2010 Apr 21. Review.

PMID:
20416328
24.

The clinical importance of nephron mass.

Luyckx VA, Brenner BM.

J Am Soc Nephrol. 2010 Jun;21(6):898-910. doi: 10.1681/ASN.2009121248. Epub 2010 Feb 11. Review.

25.

Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severity.

Warnock DG, Remuzzi G, Brenner BM, Levin A, Wanner C.

Clin J Am Soc Nephrol. 2010 Feb;5(2):359. doi: 10.2215/CJN.08191109. Epub 2009 Dec 17. No abstract available.

26.

Dual renin-angiotensin system blockade and kidney disease.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Pfeffer MA.

J Am Coll Cardiol. 2009 Jul 14;54(3):278-9; author reply 279-80. doi: 10.1016/j.jacc.2009.02.074. No abstract available.

27.

Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.

Oqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E, Wanner C, Zhang K, Warnock DG.

Nephrol Dial Transplant. 2009 Jun;24(6):1736-43. doi: 10.1093/ndt/gfp105. Epub 2009 Mar 16. Review. No abstract available.

PMID:
19293136
28.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721. Epub 2009 Jan 14.

PMID:
19145003
29.

Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability.

Swede H, Rohan TE, Yu H, Anderson JC, Stevens RG, Brokaw J, Levine J, Brenner BM, Malchoff CD, Duffy VB, Pleau DC, Rosenberg DW.

Cancer Causes Control. 2009 Jul;20(5):653-61. doi: 10.1007/s10552-008-9278-7. Epub 2008 Dec 9.

30.

Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.

Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG.

Nat Clin Pract Nephrol. 2008 Jun;4(6):327-36. doi: 10.1038/ncpneph0806. Epub 2008 Apr 22.

PMID:
18431378
31.

Renal risk scores: progress and prospects.

Taal MW, Brenner BM.

Kidney Int. 2008 Jun;73(11):1216-9. doi: 10.1038/ki.2008.36. Epub 2008 Mar 5. Review.

32.

ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.

Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, Shahinfar S, Wong PH, Lyle PA, Rossing P, Brenner BM.

J Am Soc Nephrol. 2008 Apr;19(4):771-9. doi: 10.1681/ASN.2007050582. Epub 2008 Jan 16.

33.

Defining renal risk.

Taal MW, Brenner BM.

Curr Opin Nephrol Hypertens. 2007 Nov;16(6):554-6. Review. No abstract available.

PMID:
18089970
34.

Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.

Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, Parving HH, Cooper ME, Shahinfar S, Brenner BM.

Diabetes Care. 2008 Mar;31(3):445-7. Epub 2007 Dec 10.

PMID:
18070995
35.

Fetal programming of adult kidney disease: cellular and molecular mechanisms.

Hershkovitz D, Burbea Z, Skorecki K, Brenner BM.

Clin J Am Soc Nephrol. 2007 Mar;2(2):334-42. Epub 2007 Feb 14. Review. No abstract available.

36.

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM; RENAAL Study Investigators.

Clin J Am Soc Nephrol. 2006 Jul;1(4):761-7. Epub 2006 May 17.

37.

Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.

J Am Soc Nephrol. 2007 May;18(5):1540-6. Epub 2007 Apr 4.

38.

Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.

Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de Zeeuw D.

J Hypertens. 2007 Apr;25(4):871-6.

PMID:
17351381
39.

Allelic losses at genomic instability-associated loci in villous adenomas and adjacent colorectal cancers.

Brenner BM, Stoler DL, Rodriguez L, Karpenko MJ, Swede H, Petrelli NJ, Anderson GR.

Cancer Genet Cytogenet. 2007 Apr 1;174(1):9-15.

40.

Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.

Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM.

Diabetes Care. 2006 Oct;29(10):2210-7.

PMID:
17003295
41.

Predicting initiation and progression of chronic kidney disease: Developing renal risk scores.

Taal MW, Brenner BM.

Kidney Int. 2006 Nov;70(10):1694-705. Epub 2006 Sep 13. Review.

42.

Genomic profiles of colorectal cancers differ based on patient smoking status.

Swede H, Bartos JD, Chen N, Shaukat A, Dutt SS, McQuaid DA, Natarajan N, Rodriguez-Bigas MA, Nowak NJ, Wiseman SM, Alrawi S, Brenner BM, Petrelli NJ, Cummings KM, Stoler DL, Anderson GR.

Cancer Genet Cytogenet. 2006 Jul 15;168(2):98-104.

PMID:
16843098
43.

Genomic instability of human aberrant crypt foci measured by inter-(simple sequence repeat) PCR and array-CGH.

Alrawi SJ, Carroll RE, Hill HC, Gibbs JF, Tan D, Brenner BM, Nowak NJ, Swede H, Stoler DL, Anderson GR.

Mutat Res. 2006 Oct 10;601(1-2):30-8. Epub 2006 Jun 27.

PMID:
16806294
44.

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.

Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM; RENAAL Investigators.

Pharmacoeconomics. 2006;24(6):549-58.

PMID:
16761903
45.

Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.

de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S.

Kidney Int. 2006 May;69(9):1675-82.

46.

Losartan: lessons learned from the RENAAL study.

Shahinfar S, Lyle PA, Zhang Z, Keane WF, Brenner BM.

Expert Opin Pharmacother. 2006 Apr;7(5):623-30. Review.

PMID:
16553578
47.

Renoprotective effects of renin-angiotensin-system inhibitors.

de Zeeuw D, Lewis EJ, Remuzzi G, Brenner BM, Cooper ME.

Lancet. 2006 Mar 18;367(9514):899-900; author reply 900-2. No abstract available.

PMID:
16546533
48.

Adult hypertension and kidney disease: the role of fetal programming.

Zandi-Nejad K, Luyckx VA, Brenner BM.

Hypertension. 2006 Mar;47(3):502-8. Epub 2006 Jan 16. Review.

PMID:
16415374
49.

'Hypertension' and 'microalbuminuria': the bell tolls for thee.

Forman JP, Brenner BM.

Kidney Int. 2006 Jan;69(1):22-8. Review.

50.

Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.

Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.

Am J Cardiol. 2005 Dec 1;96(11):1530-6. Epub 2005 Oct 17.

PMID:
16310435

Supplemental Content

Loading ...
Support Center